


**FOURTH
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/531,594	NOV 12 2008 U.S. PATENT & TRADEMARK OFFICE
Filing Date	November 28, 2005	
First Named Inventor	Marc Blondel et al.	
Examiner Name	Susan Marie Hanley	
Attorney Docket No.	0070663-000002	



U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Enter Office that issued the document, by the two-letter code.

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Deborah Tribouillard-Tanvier et al., "Antihypertensive Drug Guanabenz is Active <i>in vivo</i> Against Both Yeast and Mammalian Prions," (2008) PLoS ONE, 3(4):1-9, e1981
	Deborah Tribouillard-Tanvier et al., "Protein Folding Activity of Ribosomal RNA is a Selective Target of Two Unrelated Antiprion Drugs," PLoS ONE, 3(5):1-14, e2174
	Deborah Tribouillard-Tanvier et al., "Using Budding Yeast to Screen for Anti-Prion Drugs", (2006) Biotechnology Journal, 1:58-67
	Deborah Tribouillard-Tanvier et al., "Antiprion Drugs as Chemical Tools to uncover mechanisms of Prion Propagation," (2007) Prion 1:1, 48-52
	Stephane Bach et al., "Isolation of Drugs Active Against Mammalian Prions Using a Yeast-based Screening Assay," Nature Biotechnology (2003) 21(9):1075-1081

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.